Provided by Tiger Trade Technology Pte. Ltd.

Altimmune, Inc.

3.02
-0.1800-5.63%
Post-market: 3.070.0500+1.66%19:59 EDT
Volume:2.67M
Turnover:8.19M
Market Cap:392.81M
PE:-3.02
High:3.19
Open:3.16
Low:3.02
Close:3.20
52wk High:7.73
52wk Low:2.90
Shares:130.07M
Float Shares:124.00M
Volume Ratio:0.52
T/O Rate:2.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9999
EPS(LYR):-0.9999
ROE:-50.57%
ROA:-28.17%
PB:1.75
PE(LYR):-3.02

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Ideaya Biosciences, Omnicom Group, Targa Resources

Reuters
·
Dec 02, 2025

Altimmune CEO Vipin Garg to Step Down

MT Newswires Live
·
Dec 01, 2025

BUZZ-Altimmune falls as CEO Vipin Garg to step down

Reuters
·
Dec 01, 2025

BRIEF-Altimmune Announces CEO Transition, Succession Plan

Reuters
·
Dec 01, 2025

Altimmune Inc - Vipin Garg to Step Down as CEO Effective Jan 1, 2026

THOMSON REUTERS
·
Dec 01, 2025

Altimmune Inc - Vipin Garg to Serve as Advisor Through June 30, 2026

THOMSON REUTERS
·
Dec 01, 2025

Altimmune Inc - Jerry Durso to Assume Role of CEO and Retain Chairman Position

THOMSON REUTERS
·
Dec 01, 2025

Press Release: Altimmune Announces CEO Transition and Succession Plan

Dow Jones
·
Dec 01, 2025

FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats up

Reuters
·
Nov 25, 2025

Altimmune Inc Files For Mixed Shelf Of Up To $400 Million - SEC Filing

Reuters
·
Nov 20, 2025

Altimmune Amends Loan And Security Agreement With Hercules Capital - SEC Filing

Reuters
·
Nov 20, 2025

TG Therapeutics Makes 2025 Deloitte Technology Fast 500™ List of America’s Fastest-Growing Companies

GlobeNewswire
·
Nov 19, 2025

2025 Ergothioneine Brand Comprehensive Evaluation Research Report: In-depth Analysis of Seven Popular Brands Based on Ingredient Efficacy, Technological Barriers, and Market Landscape

Deep News
·
Nov 18, 2025

Altimmune Inc. Publishes Results of Phase 2b Trial of Pemvidutide in MASH

Reuters
·
Nov 11, 2025

Altimmune announces publication of IMPACT Phase 2b trial data

TIPRANKS
·
Nov 11, 2025

Altimmune Announces Publication of Impact Phase 2B Trial Data in the Lancet and Concurrent Late-Breaking Oral Presentation at Aasld the Liver Meeting® 2025

THOMSON REUTERS
·
Nov 11, 2025

Analysts Are Bullish on These Healthcare Stocks: Altimmune (ALT), Dogwood Therapeutics (DWTX)

TIPRANKS
·
Nov 08, 2025

Altimmune Is Maintained at Market Outperform by Citizens

Dow Jones
·
Nov 07, 2025

Altimmune announce results from analysis of biopsies from IMPACT Phase 2b trial

TIPRANKS
·
Nov 07, 2025

Immunocore presents Phase 1 data for hepatitis B candidate at AASLD’s The Liver Meeting

GlobeNewswire
·
Nov 07, 2025